2025.12.07

Chidamide is Included in the National Reimbursement Drug List (NRDL) as a Regular Category B Drug

Chidamide is Included in the National Reimbursement Drug List (NRDL) as a Regular Category B Drug

Full text

2025.12.05

Dr. Lu Xianping of Chipscreen Biosciences Wins the 2025 EY Entrepreneur Of The Year - Mainland China Award

Dr. Lu Xianping of Chipscreen Biosciences Wins the 2025 EY Entrepreneur Of The Year - Mainland China Award

Full text

2025.11.19

Chipscreen Biosciences Joins Hands with StoneWise to Co-build a Novel End-to-End AI-Powered Paradigm for Early-Stage Drug Discovery

Chipscreen Biosciences Joins Hands with StoneWise to Co-build a Novel End-to-End AI-Powered Paradigm for Early-Stage Drug Discovery

Full text

2025.11.15

Chipscreen Biosciences Showcases Source Innovation Achievements Including CS231295 at the 27th CHTF

Chipscreen Biosciences Showcases Source Innovation Achievements Including CS231295 at the 27th CHTF

Full text

2025.11.03

ESMO 2025 | Chidamide Combined with PD-1 Antibody Sets New Record in Treating Advanced Sarcoma: ORR 30.4%, DCR 73.9%

ESMO 2025 | Chidamide Combined with PD-1 Antibody Sets New Record in Treating Advanced Sarcoma: ORR 30.4%, DCR 73.9%

Full text

2025.10.15

ESMO 2025 | Study Results on Chidamide's HDACi+IO Strategy Selected for Proffered Paper Session

ESMO 2025 | Study Results on Chidamide's HDACi+IO Strategy Selected for Proffered Paper Session

Full text

2025.09.25

Leading with Source Innovation: Chipscreen Biosciences and Chiglitazar Sodium (Bilessglu®) Honored with A Decade of Glory for China's Innovative Drugs Awards

Leading with Source Innovation: Chipscreen Biosciences and Chiglitazar Sodium (Bilessglu®) Honored with A Decade of Glory for China's Innovative Drugs Awards

Full text

2025.08.18

Chipscreen Biosciences 2025 Innovation Summit Concludes Successfully: AI + Integrated Core Technology Platform Fuels Original New Drug Development

Chipscreen Biosciences 2025 Innovation Summit Concludes Successfully: AI + Integrated Core Technology Platform Fuels Original New Drug Development

Full text

2025.08.07

International Hepatology Journal Publishes Key Study on Chiglitazar Sodium (Bilessglu®) for MASH Treatment

International Hepatology Journal Publishes Key Study on Chiglitazar Sodium (Bilessglu®) for MASH Treatment

Full text

2025.07.31

Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development

Chipscreen Biosciences' Brain-Penetrant Aurora B Selective Inhibitor CS231295 Tablet Receives FDA IND Approval, Advancing Global Clinical Development

Full text

2025.07.27

ESMO 2025丨Chidamide HDAC+IO Study Selected for Featured Presentation

ESMO 2025丨Chidamide HDAC+IO Study Selected for Featured Presentation

Full text

2025.07.09

A Milestone in First-Line DLBCL Treatment! Topline Results from Chidamide DEB Study Achieve Primary EFS Endpoint

A Milestone in First-Line DLBCL Treatment! Topline Results from Chidamide DEB Study Achieve Primary EFS Endpoint

Full text

2025.05.31

ASCO 2025 Highlight | Complete Response Rate Surpasses 95%! Chidamide Combination Therapy Shows Promising Results in Oral Presentation for Untreated NK/T-Cell Lymphoma

ASCO 2025 Highlight | Complete Response Rate Surpasses 95%! Chidamide Combination Therapy Shows Promising Results in Oral Presentation for Untreated NK/T-Cell Lymphoma

Full text

2025.05.15

Chidamide (Epidaza®) - 19 studies to be presented at EHA 2025

Chidamide (Epidaza®) - 19 studies to be presented at EHA 2025

Full text

2025.04.18

CSCO Guidelines Major Update for First-line DLBCL: Epidaza® Receives First Authoritative Recommendation

CSCO Guidelines Major Update for First-line DLBCL: Epidaza® Receives First Authoritative Recommendation

Full text